Pharmacokinetics and safety of oral levofloxacin in human immunodeficiency virus-infected individuals receiving concomitant zidovudine.

Podobne zapisy

• Pharmacokinetic Evaluation of Oral Levofloxacin in Human Immunodeficiency Virus-Infected Subjects Receiving Concomitant Antiretroviral Therapy
  od: Villani, P., i wsp.
  Wydane: (2001)
• Pharmacokinetics and safety of levofloxacin in patients with human immunodeficiency virus infection.
  od: Goodwin, S D, i wsp.
  Wydane: (1994)
• Absence of age and gender effects on the pharmacokinetics of a single 500-milligram oral dose of levofloxacin in healthy subjects.
  od: Chien, S C, i wsp.
  Wydane: (1997)
• Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses.
  od: Chien, S C, i wsp.
  Wydane: (1997)
• Pharmacokinetics and Safety of High-Dose and Extended-Interval Regimens of Levofloxacin in Human Immunodeficiency Virus-Infected Patients
  od: Piscitelli, Stephen C., i wsp.
  Wydane: (1999)